You are here: Industry Insights > Lokelma

News List

AstraZeneca’s Lokelma approved for hyperkalaemia in Japan pharmaceutical-technology
March 27, 2020
The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) for patients with hyperkalaemia, characterised by elevated levels of potassium in the blood.
NICE recommends Lokelma treatment for hyperkalaemia europeanpharmaceuticalreview
August 05, 2019
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
Positive results for AZ’ Lokelma in hyperkalaemia pharmatimes
June 18, 2019
AstraZeneca has announced a statistically significant and clinically meaningful improvement from its Phase IIIb DIALIZE trial, investigating the efficacy and safety of Lokelma (sodium zirconium cyclosilicate) for the treatment of hyperkalaemia in patients
AZ to file potential blockbuster potassium drug in Asia pharmaphorum
December 19, 2018
AstraZeneca is planning filings of its high potassium drug Lokelma in Asia, following supportive trial findings.
EU approves AZ’ potassium binder for hyperkalaemia pharmatimes
July 20, 2018
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
USFDA approves AstraZeneca's Lokelma biospectrumasia
May 22, 2018
Lokelma is approved for the treatment of adults with hyperkalaemia
AstraZeneca’s Lokelma receives EU approval biospectrumasia
April 02, 2018
Lokelma is a highly-selective, oral potassium-removing agent. The approval is supported by data from three double-blind, placebo-controlled trials and one open-label trial, where patients with hyperkalaemia were treated for up to 12 months